PSMAfore: Lutetium-177–PSMA-617 in Metastatic CRPC

News
Video

Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Related Videos
Experts on GU Cancer
Experts on GU Cancer
Experts on GU Cancer
Expert on mUC
Expert on mUC
Expert on mUC
Expert on mUC
Expert on mUC
Related Content